# Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

> **NCT05872412** · PHASE2 · UNKNOWN · sponsor: **Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh** · enrollment: 82 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05872412
- **Lead sponsor:** Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-04-30
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05872412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05872412, "Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05872412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*